Madrigal Pharmaceuticals stock to be featured in comparative analysis at upcoming conference

Investing.com - Madrigal Pharmaceuticals (NASDAQ:MDGL), currently trading near $300 with analysts seeing up to 80% upside potential according to InvestingPro data, will present a comparative meta-analysis of its drug Rezdiffra against glucagon receptor agonists in MASLD and MASH at an upcoming medical conference on Saturday, July 12.

The presentation will be part of "The Evolving Landscape of MASLD: From Pathophysiology to Therapeutic Innovations" session, according to Citizens JMP, which reiterated its Market Outperform rating and $470.00 price target on the stock.

Rezdiffra will also be featured in two posters that will compare its efficacy to Akero’s FGF21 efruxifermin, along with a systematic review of Rezdiffra’s randomized controlled trials.

The U.S. launch of Rezdiffra has exceeded expectations with more than 17,000 patients using the drug as of last quarter, with sales beating consensus estimates.

Madrigal Pharmaceuticals is preparing for its European launch of Rezdiffra, with a regulatory decision expected in August, while recent data presented at EASL for both Rezdiffra and efruxifermin in compensated cirrhotics showed promising results.

In other recent news, Madrigal Pharmaceuticals reported stronger-than-expected financial results for the first quarter of 2025, with earnings per share (EPS) of -3.32, surpassing the forecasted -3.86. The company also reported revenue of $137.3 million, exceeding expectations of $112.54 million, marking a 33% increase from the previous quarter. Additionally, Madrigal’s resmetirom, marketed as Rezdiffra, received a recommendation for approval from the European Medicines Agency’s Committee for Medicinal Products for Human Use for treating adults with noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver fibrosis.

Analysts have maintained varying outlooks on Madrigal Pharmaceuticals. Citizens JMP reaffirmed their Market Outperform rating, while Citi maintained a Buy rating with a price target of $456, following the company’s recent investor webcast. Conversely, BofA Securities reiterated an Underperform rating with a price target of $248, citing difficulty in assessing the overall benefit of Rezdiffra and identifying the best-responding subpopulation.

Madrigal Pharmaceuticals hosted an investor call discussing their two-year study results of Rezdiffra in compensated MASH cirrhosis, highlighting positive improvements across several imaging and biomarker tests. The company continues to lead in the NASH treatment market with Rezdiffra, the first FDA-approved treatment for this condition, and is preparing for a potential European launch in the second half of 2025. These developments reflect Madrigal’s ongoing efforts to expand its market presence and address unmet needs in liver disease treatment.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.